Cancer Discov

• 

  Publication Venue For

  • Diet and Exercise in Cancer Metabolism..  12:2249-2257. 2022
  • SETD2 Haploinsufficiency Enhances Germinal Center-Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis..  12:1782-1803. 2022
  • Rlf-Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer..  11:3214-3229. 2021
  • Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown..  11:2828-2845. 2021
  • The Complex Integration of T-cell Metabolism and Immunotherapy..  11:1636-1643. 2021
  • Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade..  10:1842-1853. 2020
  • The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies..  10:1894-1911. 2020
  • Hitting Gliomas When They Are Down: Exploiting IDH-Mutant Metabolic Vulnerabilities..  10:1629-1631. 2020
  • Identification of BBOX1 as a Therapeutic Target in Triple-Negative Breast Cancer..  10:1706-1721. 2020
  • Epigenetic Switch-Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer..  10:1312-1329. 2020
  • ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic Cancer..  10:142-157. 2020
  • Novel MYC-Targeting Drug Is Effective in Mouse Prostate Cancer Models..  10:15. 2020
  • Mitochondrial Homeostasis in AML and Gasping for Response in Resistance to BCL2 Blockade..  9:831-833. 2019
  • TET2 Deficiency Sets the Stage for B-cell Lymphoma..  8:1515-1517. 2018
  • Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer..  8:1176-1193. 2018
  • Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer..  8:1112-1129. 2018
  • EGFR Amplification as a Target in Gastroesophageal Adenocarcinoma: Do Anti-EGFR Therapies Deserve a Second Chance?.  8:679-681. 2018
  • Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer..  8:164-173. 2018
  • VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma..  7:1284-1305. 2017
  • Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma..  7:1116-1135. 2017
  • Identification of a DNA Damage-Induced Alternative Splicing Pathway That Regulates p53 and Cellular Senescence Markers..  7:766-781. 2017
  • Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma..  7:630-651. 2017
  • The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function..  7:424-441. 2017
  • The Genetic Basis of Hepatosplenic T-cell Lymphoma..  7:369-379. 2017
  • Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells..  7:72-85. 2017
  • Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression..  6:1022-1035. 2016
  • Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types..  6:1052-1067. 2016
  • In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes..  5:740-751. 2015
  • Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis..  5:550-563. 2015
  • Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes..  4:1398-1405. 2014
  • Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma..  4:1418-1429. 2014
  • Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition..  4:896-904. 2014
  • SPSB1 promotes breast cancer recurrence by potentiating c-MET signaling..  4:790-803. 2014
  • mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1..  4:42-52. 2014
  • Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors..  3:1355-1363. 2013
  • Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers..  3:1044-1057. 2013
  • Pten-null tumors cohabiting the same lung display differential AKT activation and sensitivity to dietary restriction..  3:908-921. 2013
  • Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma..  2:591-597. 2012
  • Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma..  1:236-247. 2011
  • Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy..  1:54-67. 2011